Evaxion A/S (NASDAQ:EVAX – Get Free Report) and Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, valuation, analyst recommendations, dividends and institutional ownership.
Risk & Volatility
Evaxion A/S has a beta of 0.26, meaning that its stock price is 74% less volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500.
Insider & Institutional Ownership
11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evaxion A/S | $7.53 million | 3.47 | -$7.71 million | ($1.21) | -2.59 |
| Taysha Gene Therapies | $9.77 million | 167.42 | -$109.00 million | ($0.42) | -11.95 |
Evaxion A/S has higher earnings, but lower revenue than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Evaxion A/S, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Evaxion A/S and Taysha Gene Therapies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evaxion A/S | N/A | -61.43% | -34.23% |
| Taysha Gene Therapies | N/A | -56.19% | -41.84% |
Analyst Ratings
This is a summary of current recommendations for Evaxion A/S and Taysha Gene Therapies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evaxion A/S | 1 | 0 | 5 | 0 | 2.67 |
| Taysha Gene Therapies | 1 | 0 | 11 | 2 | 3.00 |
Evaxion A/S presently has a consensus target price of $11.00, suggesting a potential upside of 251.44%. Taysha Gene Therapies has a consensus target price of $12.77, suggesting a potential upside of 154.37%. Given Evaxion A/S’s higher possible upside, analysts plainly believe Evaxion A/S is more favorable than Taysha Gene Therapies.
Summary
Taysha Gene Therapies beats Evaxion A/S on 9 of the 14 factors compared between the two stocks.
About Evaxion A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
About Taysha Gene Therapies
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Receive News & Ratings for Evaxion A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion A/S and related companies with MarketBeat.com's FREE daily email newsletter.
